

PATENT COOPERATION TREATY

VB

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:
BETH L. KELLY
TOWNSEND AND TOWNSEND AND CREW LLP
TWO EMBARCADERO CENTER, 8TH FLOOR
SAN FRANCISCO, CA 94111-3834

PCT

NOTIFICATION OF TRANSMITTAL OF INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter II of the Patent Cooperation Treaty)

(PCT Rule 71.1)

Date of mailing
(day/month/year) **09 MAY 2007**

Applicant's or agent's file reference

19957-016830PC

IMPORTANT NOTIFICATION

International application No.

PCT/US05/03856

International filing date (day/month/year)

04 February 2005 (04.02.2005)

Priority date (day/month/year)

04 February 2004 (04.02.2004)

Applicant

NEOSE TECHNOLOGIES, INC

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary report on patentability and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.
4. **REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the *PCT Applicant's Guide*.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed invention is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the IPEA/ US

Mail Stop PCT, Attn: IPEA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (571) 273-3201

Authorized officer

Ponnathapu Achutamurthy

Telephone No. 571-272-1261

Form PCT/IPEA/416 (January 2004)

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 19957-016830PC	FOR FURTHER ACTION		See Form PCT/IPEA/416																
International application No. PCT/US05/03856	International filing date (day/month/year) 04 February 2005 (04.02.2005)	Priority date (day/month/year) 04 February 2004 (04.02.2004)																	
International Patent Classification (IPC) or national classification and IPC IPC: C12N 15/00(2006.01),C12Q 1/48 C12P 19/44(2006.01),C12P 1/00 USPC: 435/440,435/15,435/74,435/41																			
Applicant NEOSE TECHNOLOGIES, INC																			
<ol style="list-style-type: none"> 1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36. 2. This REPORT consists of a total of <u>1</u> sheets, including this cover sheet. 3. This report is also accompanied by ANNEXES, comprising: <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> (sent to the applicant and to the International Bureau) a total of <u>22</u> sheets, as follows: <div style="margin-left: 20px;"> <input type="checkbox"/> sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions). <input type="checkbox"/> sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box. </div> b. <input type="checkbox"/> (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)) _____, containing a sequence listing and/or tables related thereto, in electronic form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions). 4. This report contains indications relating to the following items: <table style="margin-left: 20px; border: none;"> <tr> <td><input checked="" type="checkbox"/> Box No. I</td> <td>Basis of the report</td> </tr> <tr> <td><input type="checkbox"/> Box No. II</td> <td>Priority</td> </tr> <tr> <td><input checked="" type="checkbox"/> Box No. III</td> <td>Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</td> </tr> <tr> <td><input type="checkbox"/> Box No. IV</td> <td>Lack of unity of invention</td> </tr> <tr> <td><input checked="" type="checkbox"/> Box No. V</td> <td>Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</td> </tr> <tr> <td><input type="checkbox"/> Box No. VI</td> <td>Certain documents cited</td> </tr> <tr> <td><input type="checkbox"/> Box No. VII</td> <td>Certain defects in the international application</td> </tr> <tr> <td><input type="checkbox"/> Box No. VIII</td> <td>Certain observations on the international application</td> </tr> </table> 				<input checked="" type="checkbox"/> Box No. I	Basis of the report	<input type="checkbox"/> Box No. II	Priority	<input checked="" type="checkbox"/> Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability	<input type="checkbox"/> Box No. IV	Lack of unity of invention	<input checked="" type="checkbox"/> Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement	<input type="checkbox"/> Box No. VI	Certain documents cited	<input type="checkbox"/> Box No. VII	Certain defects in the international application	<input type="checkbox"/> Box No. VIII	Certain observations on the international application
<input checked="" type="checkbox"/> Box No. I	Basis of the report																		
<input type="checkbox"/> Box No. II	Priority																		
<input checked="" type="checkbox"/> Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability																		
<input type="checkbox"/> Box No. IV	Lack of unity of invention																		
<input checked="" type="checkbox"/> Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement																		
<input type="checkbox"/> Box No. VI	Certain documents cited																		
<input type="checkbox"/> Box No. VII	Certain defects in the international application																		
<input type="checkbox"/> Box No. VIII	Certain observations on the international application																		
Date of submission of the demand 26 May 2005 (26.05.2005)		Date of completion of this report 17 April 2007 (17.04.2007)																	
Name and mailing address of the IPEA/ US Mail Stop PCT, Attn: IPEA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201		Authorized officer Ponnathapu Achutamurthy Telephone No. 571-272-1261																	

Form PCT/IPEA/409 (cover sheet)(April 2005)

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/US05/03856

Box No. I Basis of the report

1. With regard to the **language**, this report is based on:

- ☒ the international application in the language in which it was filed.
- ☐ a translation of the international application into _____, which is the language of a translation furnished for the purposes of:
- ☐ international search (under Rules 12.3 and 23.1(b))
 - ☐ publication of the international application (under Rule 12.4(a))
 - ☐ international preliminary examination (under Rules 55.2(a) and/or 55.3(a))

2. With regard to the **elements** of the international application, this report is based on *(replacement sheets which have been furnished to the receiving office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report)*:☐ the international application as originally filed/furnished☒ the description:

pages 1-9, 15-22, 42, 45-59, 61-71, 73, 76-77, 80-88, 90-104 _____ as originally filed/furnished

pages* 10, 10a, 11-14, 14a, 43-44, 60-60a, 72-72a, 74-74a, 75, 78-78a, 79-79a, 89-89a _____ received by this Authority on May
26, 2005pages* NONE received by this Authority on _____☒ the claims:

pages 100-103 _____ as originally filed/furnished

pages* NONE as amended (together with any statement) under Article 19pages* NONE received by this Authority on _____pages* NONE received by this Authority on _____☒ the drawings:

pages 1-45, 47-52, 54 _____ as originally filed/furnished

pages* _____ received by this Authority on _____

pages* NONE received by this Authority on _____☐ a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.3. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages _____
- ☐ the claims, Nos. _____
- ☐ the drawings, sheets/figs _____
- ☐ the sequence listing (*specify*): _____
- ☐ any table(s) related to the sequence listing (*specify*): _____

4. ☐ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).

- ☐ the description, pages _____
- ☐ the claims, Nos. _____
- ☐ the drawings, sheets/figs _____
- ☐ the sequence listing (*specify*): _____
- ☐ any table(s) related to the sequence listing (*specify*): _____

* If item 4 applies, some or all of those sheets may be marked "superseded."

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/US05/03856

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application
☒ claims Nos. 15-33

because:

- ☐ the said international application, or the said claim Nos. 15-33 relate to the following subject matter which does not require an international preliminary examination (*specify*):

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. _____ are so unclear that no meaningful opinion could be formed (*specify*):

Claims 15-33 comprise non elected subject matters (see PCT 206 and PCT 210) for which applicant did not pay additional fees and international examination authority did not search them during international search.

- ☐ the claims, or said claims Nos. _____ are so inadequately supported by the description that no meaningful opinion could be formed (*specify*):

- ☒ no international search report has been established for said claims Nos. 15-33

- ☐ a meaningful opinion could not be formed without the sequence listing; the applicant did not, within the prescribed time limit:

- ☐ furnish a sequence listing on paper complying with the standard provided for in Annex C of the Administrative Instructions, and such listing was not available to the International Preliminary Examining Authority in a form and manner acceptable to it.

- ☐ furnish a sequence listing in electronic form complying with the standard provided for in Annex C of the Administrative Instructions, and such listing was not available to the International Preliminary Examining Authority in a form and manner acceptable to it.

- ☐ pay the required late furnishing fee for the furnishing of a sequence listing in response to an invitation under Rules 13ter.1(a) or (b) and 13ter.2.

- ☐ a meaningful opinion could not be formed without the tables related to the sequence listings; the applicant did not, within the prescribed time limit, furnish such tables in electronic form complying with the technical requirements provided for in Annex C-bis of the Administrative Instructions, and such tables were not available to the International Preliminary Examining Authority in a form and manner acceptable to it.

- ☐ the tables related to the nucleotide and/or amino acid sequence listing, if in electronic form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.

- ☐ See Supplemental Box for further details

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/US05/03856**Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)

Claims 1-14 YESClaims NONE NO

Inventive Step (IS)

Claims 1-14 YESClaims NONE NO

Industrial Applicability (IA)

Claims 1-14 YESClaims NONE NO

2. Citations and Explanations (Rule 70.7)

Claims 1-14 meet the criteria set out in PCT Articles 33(2)-(3), because the prior art does not teach or fairly suggest teaching of the method of refolding recombinant glycosyltransferase comprising a maltose binding domain by using a refolding buffer comprising redox couple and wherein said transferase transfer a sugar from donor substrate to acceptor substrate.

Claims 1-14 meet the criteria set out in PCT Articles 33(4), because the method of refolding recombinant glycosyltransferase comprising a maltose binding domain by using a refolding buffer comprising redox couple and wherein said transferase transfer a sugar from donor substrate to acceptor substrate has industrial applicability subject matter claimed can be made or use in industry.

PATENT COOPERATION TREATY

PCT

NOTE ON INFORMAL COMMUNICATION WITH THE APPLICANT

(PCT Rule 66.6)

International application No. PCT/US05/03856	Applicant's or agent's file reference 19957-016830PC	Date of informal communication (day/month/year) 3/30/2007
Applicant NEOSE TECHNOLOGIES, INC		

Communication <input checked="" type="checkbox"/> by telephone <input type="checkbox"/> personal	Participants <input type="checkbox"/> identity checked <input type="checkbox"/> authorization checked <input type="checkbox"/> personally known <input type="checkbox"/> Applicant: NEOSE TECHNOLOGIES, INC <input type="checkbox"/> Agent: <input type="checkbox"/> Examiner(s):
---	--

Summary of communication:

Applicant suggested to submit a 409 IPER on searched claims 1-11.

- ☐ An extension of time limit is granted (Form PCT/IPEA/427).
- ☒ A copy of this note is being sent to the applicant with Form PCT/IPEA/429.

Applicant/Agent	Authorized officer of IPEA/ Ponnathapu Achutamurthy Telephone No. 571-272-1261
-----------------	--

PCT/US05/03456, 251052005

[0061] Figure 5 provides the results of an assay of GlycoPEGylation of EPO using the refolded SuperGlycoMix. Lanes are as follows: (1) MW markers, SeeBlue2 Invitrogen,(250, 148, 98, 64, 50, 36, 22, 16, 6 kD); (2) Positive control with EPO, + NSO expressed GalT1, BV GnT1, *Aspergillus* ST3GalIII and sugar nucleotides; (3) Negative control, Same as 2 without UDP-GlcNAc; (4) EPO, Purified and separately refolded MBP-GalT1(Δ 129) C342T, Refolded MBP-GnT1(Δ 103), and *Aspergillus niger* expressed ST3GalIII; (5) EPO, SuperGlycoMix (mixture of MBP-ST3GalIII, MBP-GalT1(Δ 129) C342T, MBP-GnT1(Δ 103)C123A and sugar nucleotides.

[0062] Figure 6 provides an alignment of a human GnT1 amino acid sequence (top line, NP_002397; SEQ ID NO:1) and a rabbit GnT1 amino acid sequence (bottom line, P27115; SEQ ID NO:2). The conserved unpaired cysteines are underlined and in bold text.

[0063] Figure 7 provides the amino acid sequence (SEQ ID NO:3) of a GnT1 Cys121Ser mutant and a nucleic acid sequence (SEQ ID NO:4) that encodes the mutant GnT1 protein. The amino acid sequence depicted begins with amino acid residue 104 of the full length human protein and is representative of mammalian GnT1 proteins with the following unpaired cysteine mutation: ...stvrrsldklh... (SEQ ID NO:5), where the bold residue is mutated from the wild-type cysteine.

[0064] Figure 8 provides the amino acid sequence (SEQ ID NO:6) of a GnT1 Cys121Asp mutant and a nucleic acid sequence (SEQ ID NO:7) that encodes the mutant GnT1 protein. The amino acid sequence depicted begins with amino acid residue 104 of the full length human protein and is representative of mammalian GnT1 proteins with the following unpaired cysteine mutation: ...stvrrldklh... (SEQ ID NO:8), where the bold residue is mutated from the wild-type cysteine.

[0065] Figure 9 provides the amino acid sequence (SEQ ID NO:9) of a GnT1 Cys121Thr mutant and a nucleic acid sequence (SEQ ID NO:10) that encodes the mutant GnT1 protein. The amino acid sequence depicted begins with amino acid residue 104 of the full length human protein and is representative of mammalian GnT1 proteins with the following unpaired cysteine mutation: ...stvrrldklh...(SEQ ID NO:11), where the bold residue is mutated from the wild-type cysteine.

[0066] Figure 10 provides the amino acid sequence (SEQ ID NO:12) of a GnT1 Cys121Ala mutant and a nucleic acid sequence (SEQ ID NO:13) that encodes the mutant GnT1 protein.

The amino acid sequence depicted begins with amino acid residue 104 of the full length human protein and is representative of mammalian GnT1 proteins with the following unpaired cysteine mutation: ...stvrraldkllh... (SEQ ID NO:14), where the bold residue is mutated from the wild-type cysteine.

FIG. 11: 1505/03856, 26052, 015

[0067] Figure 11 provides the amino acid sequence (SEQ ID NO:15) of a GnT1 Arg120Ala, Cys121His mutant and a nucleic acid sequence (SEQ ID NO:16) that encodes the mutant GnT1 protein. The amino acid sequence depicted begins with amino acid residue 104 of the full length human protein and is representative of mammalian GnT1 proteins with the following double mutation: ...stvr**ah**ldklh... (SEQ ID NO:17), where the bold residue is mutated from the wild-type cysteine.

[0068] Figure 12 provides the amino acid sequence of rat liver ST3GalIII (SEQ ID NO:18). The underlined and italicized sequence was deleted to make the Δ 28 deletion.

[0069] Figures 13A and 13B provide full length nucleic acid (SEQ ID NO:20) and amino acid (SEQ ID NO:19) sequences of UDP-N-acetylgalactosaminyltransferase 2 (GalNAcT2). The accession number of the nucleic acid and protein is NM_004481.

[0070] Figures 14A and 14B provide nucleic acid (SEQ ID NO:22) and amino acid (SEQ ID NO:21) sequences of a Δ 51GalNAcT2. The numbering is based on the full length amino acid and nucleic acid sequences shown in Figures 13A and B.

[0071] Figure 15 provides a demonstration of the protein concentration of refolded MBP-GalNAcT2(D51) after solubilization at pH 6.5 or pH 8.0 and refolding at pH 6.5 or pH 8.0. The pH values tested are expressed as solubilization pH-refolding pH. Protein concentrations were measured immediately after refolding (light gray bars), after dialysis (dark gray bars), and after concentration (white bars).

[0072] Figure 16 provides a demonstration of the enzymatic activity of refolded MBP-GalNAcT2(D51) after solubilization at pH 6.5 or pH 8.0 and refolding at pH 6.5 or pH 8.0. The pH values tested are expressed as solubilization pH-refolding pH. Activity was measured after dialysis (light gray bars) and after concentration (dark gray bars).

[0073] Figure 17 provides a demonstration of the specific activity of refolded MBP-GalNAcT2(D51) after solubilization at pH 6.5 or pH 8.0 and refolding at pH 6.5 or pH 8.0. The pH values tested are expressed as solubilization pH-refolding pH. Specific activity was measured after dialysis (white bars) and after concentration (dark gray bars).

[0074] Figures 18A and 18B provide results of remodeling of recombinant granulocyte colony stimulating factor (GCSF) using refolded MBP-GalNAcT2(D51) after solubilization at pH 6.5 or pH 8.0 and refolding at pH 6.5 or pH 8.0. Figure 18A shows the results using a control purified MBP-GalNAcT2(D51), or a negative control that lacked a substrate, or

bacterially expressed MBP-GalNAcT2(D51) that was solubilized at pH 6.5 and refolded at pH 6.5. Figure 18B shows the experimental results.

[0075] Figure 19 provides a profile of refolded MBP-GalNAcT2(D51) proteins after elution from a Q Sepharose XL (QXL) column (Amersham Biosciences, Piscataway, NJ).

5 The top of the figure shows a chromatogram illustrating the elution of MBP-GalNAcT2(D51) from the QXL column. Fraction numbers are indicated on the X-axis and the relative absorbance of each fraction is indicated on the Y-axis. The bottom shows an image of two electrophoretic gels used to visualize the eluted fractions. The contents of each lane on the gel are described in the figure.

10 [0076] Figure 20 provides the GalNAcT2 activity of specific column fractions from the QXL column shown in Figure 19. The most active fractions were applied to a Hydroxyapatite Type I (80 μ m) (BioRad, Hercules, CA) column.

[0077] Figure 21 provides a profile of refolded MBP-GalNAcT2(D51) proteins after elution from the HA type I column. The top of the figure shows a chromatogram illustrating
15 the elution of MBP-GalNAcT2(D51) from the HA type I column. Fraction numbers are indicated on the X-axis and the relative absorbance of each fraction is indicated on the Y-axis. The bottom shows an image of an electrophoretic gel used to visualize the eluted fractions. The contents of each lane on the gel are described in the figure.

[0078] Figure 22 provides the GalNAcT2 activity of HA type I eluted fractions.

20 [0079] Figure 23 provides a comparison of purification and activity of ST3Gal3 proteins fused to either an MBP tag or to an MBP-SBD tag.

[0080] Figure 24 provides the amino acid sequences of the MBP-ST3Gal1 fusion protein (SEQ ID NO:23) (A) and the MBP-SBD-ST3Gal1 fusion protein (SEQ ID NO:24) (B).

[0081] Figure 25 provides the sialyltransferase activity of the MBP-ST3Gal3 fusion
25 protein) and the MBP-SBD-ST3Gal3 fusion protein. positive and negative controls are also shown.

[0082] Figure 26 provides the amino acid sequence of mouse and human ST6GalNAcI proteins fused to MBP. Part A shows the sequence of a mouse truncation fusion: MBP-mST6GalNAcI S127 (SEQ ID NO:25). Part B shows the sequence of a human truncation
30 fusion: MBP-hST6GalNAcI K36 (SEQ ID NO:26).

PCT/US05/03856 25052005

[0083] Figure 27 provides SDS-PAGE gels of O-linked glycosyltransferase enzyme (A) concentrations after co-refolding and the (B) results of an enzyme assay after co-refolding. MBP-GalNAcT2 and MBP-ST3GalI were co-refolded together. Enzyme activity was tested after addition of Core I Gal T1 enzyme. The substrates were IF α -2b and 20K-Peg-CMP-NAN.

[0084] Figure 28 provides an SDS-PAGE gel showing expression of the native SiaA protein in *E. coli* before and after induction with IPTG.

[0085] Figure 29 provides an SDS-PAGE gel showing expression of an MBP-SiaA fusion protein in *E. coli* before and after induction with IPTG.

[0086] Figure 30 provides the amino acid sequence of the full length bovine GalT1 protein (SEQ ID NO:27).

[0087] Figure 31 depicts GalT1 mutants schematically, as well as a control protein GalT1(40) (S96A+C342T).

[0088] Figure 32 provides the results of enzymatic assays of the refolded and purified MBP-GalT1 (D70) protein. The assay measured conversion of LNT2 (Lacto-N-Triose-2) into LNnT (Lacto-N-Neotetraose) using UDP-Gal (Uridine 5'-Diphosphogalactose) as a donor substrate.

[0089] Figure 33 provides an RNase B remodeling assay of MBP-GalT1 (D70) and a control protein GalT1(40) (S96A+C342T), also referred to as Qasba's GalT1.

[0090] Figure 34 provides kinetics of glycosylation of RNase B using the refolded and purified MBP-GalT1 (D70) protein or NSO GalT1, a soluble form of the bovine GalT1 protein that was expressed in a mammalian cell system.

[0091] Figure 35 provides a schematic of the MBP-GnT1 fusion proteins, and depicts the truncations, e.g., Δ 103 or Δ 35, and the Cys121Ser mutation (top). The bottom of the figure provides the full length human GnT1 protein (SEQ ID NO:1).

[0092] Figure 36 provides an SDS-PAGE gel showing in the right panel the refolded MBP-GnT1 fusion proteins: MBP-GnT1(D35) C121A, MBP-GnT1(D103) R120A + C121H, and MBP-GnT1(D103) C121A. The left panel shows GnT1 activities of two different batches (A1 and A2) of refolded MBP-GnT1(D35) C121A at different time points.

[0093] Figure 37 provides a full length sequence of porcine ST3Gal1 (SEQ ID NO:28).

[0094] Figure 38 provides full length amino acid sequences for A) human ST6GalNAcTI (SEQ ID NO:29) and for B) chicken ST6GalNAcTI (SEQ ID NO:30), and C) a sequence of the mouse ST6GalNAcTI protein beginning at residue 32 of the native mouse protein (SEQ ID NO:31).

5 [0095] Figure 39 provides a schematic of a number of preferred human ST6GalNAcI truncation mutants.

[0096] Figure 40 shows a schematic of MBP fusion proteins including the human ST6GalNAcI truncation mutants.

10 [0097] Figure 41 provides the full length sequence of human Core 1 GalT1 protein (SEQ ID NO:32).

[0098] Figure 42 provides the sequences of two Drosophila Core 1 GalT1 proteins (SEQ ID NOS:33 and 34).

15 [0099] Figure 43 provides the sequences of exemplary bacterial MBP proteins that can be fused to glycosyltransferases to enhance refolding. A. *Yersinia* MBP (SEQ ID NO:35); B. *E. coli* MBP (SEQ ID NO:36); C. *Pyrococcus furiosus* MBP (SEQ ID NO:37); D. *Thermococcus litoralis* MBP (SEQ ID NO:38); E. *Thermatoga maritime* MBP (SEQ ID NO:39); and F. *Vibrio cholerae* MBP (SEQ ID NO:40).

20 [0100] Figure 44 provides an alignment of human GalNAcT1 (SEQ ID NO:41) and GalNAcT2 proteins (SEQ ID NO:19). Because the alignment programs account for sequence insertions or deletions, the numbering of cysteine residues is not the same as mentioned text and published sequences. In the case of hGalNAc-T2 cysteine 227 (published) corresponds to position 235 in the alignment and cysteine 229 (published) is 237 in the alignment. The hGalNAc-T1 cysteines are 212 (published), which corresponds to cysteine 235 (alignment) and 214 (published), which corresponds to cysteine 237 (alignment). The relevant cysteine
25 residues are indicated by larger font size. Consensus peptides = SEQ ID NOS:42-65.

[0101] Figure 45 shows the position of paired and unpaired cysteine residues in the human ST6GalNAcI protein. Single and double cysteine substitution are also shown, e.g., C280S, C362S, C362T, (C280S + C362S), and (C280S + C362T).

DEFINITIONS

[0102] The recombinant glycosyltransferase proteins of the invention are useful for transferring a saccharide from a donor substrate to an acceptor substrate. The addition generally takes place at the non-reducing end of an oligosaccharide or carbohydrate moiety on a biomolecule. Biomolecules as defined here include but are not limited to biologically

5

about amino acid residues 32-90. Thus, a truncated human Core1 GalT1 protein can have deletions at the amino terminus of about *e.g.*, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, or 90 residues.

- 5 [0210] Deletion mutations can also be made in an ST3Gal1 protein. For example, the human ST3Gal1 protein includes a stem region from about amino acid residues 18-58. Thus, a truncated human ST3Gal1 protein can have deletions at the amino terminus of about *e.g.*, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 56, 57, or 58 residues. As another example, the
- 10 porcine ST3Gal1 protein includes a stem region from about amino acid residues 28-61. Thus, a truncated porcine ST3Gal1 protein can have deletions at the amino terminus of about *e.g.*, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 56, 57, 58, 59, 60, or 61 residues.

- [0211] Deletion mutations can also be made in a GalNAcT2 protein. For example, the rat
- 15 GalNAcT2 protein includes a stem region from about amino acid residues 40-95. Thus, a truncated rat GalNAcT2 protein can have deletions at the amino terminus of about *e.g.*, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95 residues.

- 20 [0212] Deletion mutations can also be made in an ST6GalNAcI protein. For example, the mouse ST6GalNAcI protein includes a stem region from about amino acid residues 30-207. Thus, a truncated mouse ST6GalNAcI protein can have deletions at the amino terminus of about *e.g.*, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77,
- 25 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174,
- 30 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, or 207 residues. As another example, the human ST6GalNAcI protein includes a stem region from about amino

acid residues 35-278. Thus, a truncated human ST6GalNAcI protein can have deletions at the amino terminus of about *e.g.*, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, or 278 residues. As still another example, chicken ST6GalNAcI protein includes a stem region from about amino acid residues 37-253. Thus, a truncated chicken ST6GalNAcI protein can have deletions at the amino terminus of about *e.g.*, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, or 253 residues.

D. *One pot refolding of glycosyltransferases*

[0213] These embodiments of the invention are based on the surprising observation that multiple eukaryotic glycosyltransferases expressed in bacterial inclusion bodies can be refolded in a single vessel, *i.e.*, a one pot method. Using this method at least two glycosyltransferases can be refolded together resulting in savings of time and materials.

PCT/US95/03856, 25052705

residues of the yeast ubiquitin gene containing a peptidase cleavage site. Cleavage at the junction of the two moieties results in production of a protein having an intact authentic N-terminal residue.

[0259] The expression vectors of the invention can be transferred into the chosen host cell by well-known methods such as calcium chloride transformation for *E. coli* and calcium phosphate treatment or electroporation for mammalian cells. Cells transformed by the plasmids can be selected by resistance to antibiotics conferred by genes contained on the plasmids, such as the *amp*, *gpt*, *neo* and *hyg* genes.

VI. Proteins and protein purification

[0260] The recombinant eukaryotic glycosyltransferase proteins can be purified according to standard procedures of the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis and the like (*see, generally, R. Scopes, Protein Purification*, Springer-Verlag, N.Y. (1982), Deutscher, *Methods in Enzymology Vol. 182: Guide to Protein Purification*, Academic Press, Inc. N.Y. (1990)). In preferred embodiments, purification of the recombinant eukaryotic glycosyltransferase proteins occurs after refolding of the protein. Substantially pure compositions of at least about 70 to 90%, homogeneity are preferred; more preferably at least 91%, 92%, 93%, 94%, 95%, 96%, or 97%; and 98 to 99% or more homogeneity are most preferred. The purified proteins may also be used, *e.g.*, as immunogens for antibody production.

[0261] To facilitate purification of the recombinant eukaryotic glycosyltransferase proteins of the invention, the nucleic acids that encode the recombinant eukaryotic glycosyltransferase proteins can also include a coding sequence for an epitope or "tag" for which an affinity binding reagent is available, *i.e.* a purification tag. Examples of suitable epitopes include the myc and V-5 reporter genes; expression vectors useful for recombinant production of fusion proteins having these epitopes are commercially available (*e.g.*, Invitrogen (Carlsbad CA) vectors pcDNA3.1/Myc-His and pcDNA3.1/V5-His are suitable for expression in mammalian cells). Additional expression vectors suitable for attaching a tag to the fusion proteins of the invention, and corresponding detection systems are known to those of skill in the art, and several are commercially available (*e.g.*, "FLAG" (Kodak, Rochester NY).

Another example of a suitable tag is a polyhistidine sequence, which is capable of binding to metal chelate affinity ligands. Typically, six adjacent histidines (SEQ ID NO:67) are used,

PC T/US05-03055-26052105

although one can use more or less than six. Suitable metal chelate affinity ligands that can serve as the binding

PCT:US05/03446 - 26052005

enzyme, GST-ST3-GalIII, was active and transferred sialic acid to an LNnT sugar substrate and to asialylated glycoproteins, for example, transferrin and Factor IX.

Cloning ST3GalIII into pGEX-Xt-KT vector

[0305] Rat liver ST3-GalIII gene was cloned into *Bam*H1 and *Eco*R1 sites of the pGEX-KT-Ext vector after PCR Amplification using the following primers:

Sense Sial 5'Tm 5'-TTTGGATCCAAGCTACACTTACTCCAATGG (SEQ ID NO:68)
Antisense: Sial 3' Whole 5'-TTTGAATTCTCAGATACCACTGCTTAAGTC (SEQ ID NO:69)

Expression of GST-ST3GalIII in *E. coli* BL21 cells

[0306] pGEX-ST3GalIII, an expression vector comprising the ST3GalIII GST fusion, was transformed into chemically competent *E. coli* BL21 cells. Single colonies were picked, inoculated into five ml LB media with 100 µg/ml carbenicillin, and grown overnight at 37°C with shaking. The next day, one ml of overnight culture was transferred into one liter of LB media with 100 µg/ml carbenicillin. Bacteria were grown until to an OD₆₂₀ of 0.7, then 150 µM IPTG (final) was added to the medium. Bacteria were grown at 37°C for one to two hours more, then shifted to room temperature and grown overnight with shaking. Cells were harvested by centrifugation; bacterial pellets were resuspended in PBS buffer and lysed using a French Press. Soluble and insoluble fractions were separated by centrifugation for thirty minutes at 10,000 RPM in a Sorvall, SS 34 rotor at 4°C.

Purification of the inclusion bodies

[0307] Fifty ml of Novagen's Wash buffer (20 mM Tris.HCl, pH 7.5, 10 mM EDTA, 1 % Triton X-100) was added to the insoluble fraction, *i.e.*, the inclusion bodies (IB's). The insoluble fraction was vortexed to resuspend the pellet. The suspended IB's were centrifuged and washed at least twice by resuspending in Wash Buffer as above. Clean precipitates (IB's) were recovered and were stored at -20 °C until use.

Refolding inclusion bodies

[0308] The IB's were weighed (144 mg) and dissolved in Genotech IBS buffer (1.44 ml). The resuspended IB's were incubated at 4 °C for one hour in an Eppendorf centrifuge tube. Insoluble material was removed by centrifugation at maximum speed in an Eppendorf centrifuge. Solubilized IB's were diluted to 4 ml final volume. Refolding of GST-ST3GalIII was tested in refolding buffer solutions containing cyclodextrin, polyethylene glycol (PEG),

PCT, US05,034565, 26052705

ND SB-201, or a GSH/GSSG redox system. One ml of solubilized IB's were diluted rapidly by pipetting into the refolding solution, vigorously mixed for 30-40 seconds, and then gently

Table 3. GST-ST3GalIII activities after two separate folding experiments using GSH/GSSG system.

GSH/GSSG	Conc	Activity
Refolding Trial 1	12x	182 U/L*
Refolding Trial 2	40x	531 U/L*

*Activities reported here are Units per L refolded enzyme

Sialylation of glycoproteins using refolded GST-ST3 Gal III

[0311] Twenty μL of asialylated Transferrin ($2\mu\text{g}/\mu\text{L}$) or asialylated Factor IX ($2\mu\text{g}/\mu\text{L}$), was added to fifty μL of a buffer containing 50mM Tris, pH 8.0; and 150 mM NaCl, with 10 μL of 100 mM MnCl_2 ; 10 μL of 200mM CMP-NAN; and 0.05% sodium azide. The reaction mixture was incubated with 30 μL refolded GST-ST3GalIII at 30°C overnight or longer with shaking at 250 rpm. After the reactions were stopped, the sialylated proteins were separated on pH 7-3 IEF (Isoelectric focusing gel, Invitrogen) and stained with Comassie Blue according to manufacturer's guideline. Both Transferrin and Factor IX were sialylated by GST-ST3GalIII. (Data not shown.)

Refolding a rat liver ST3GalIII fused to an MBP tag.

[0312] Rat liver ST3GalIII was cloned into pMAL-c2x vector and expressed as a maltose binding protein (MBP) fusion, MBP-ST3GalIII, in inclusion bodies of *E.coli* TB1 cells. The refolded MBP-ST3GalIII was active and transferred sialic acid to LNT, a sugar substrate, and to asialylated glycoproteins, for example asialo-transferrin.

Cloning ST3GalIII into pMAL-c2x vector

[0313] The rat liver ST3-GalIII nucleic acid was cloned into *Bam*H1 and *Xba*I sites of the pMAL-c2x vector after PCR Amplification using the following primers:

Sense ST3BAMH1 5'-TAATGGATTCAAGCTACACTTACTCCAATGG (SEQ ID NO:70)
Antisense: ST3XBA1 5'-GCGCTCTAGATCAGATACCACTGCTTAAGT (SEQ ID NO:71)

[0314] Nucleotides encoding amino acids 28-374, e.g., the stem region and catalytic domain of ST3GalIII, were fused to the MBP amino acid tag.

[0315] Three other truncations of ST3GalIII were constructed and fused to MBP. The three ST3Gal III ($\Delta 73$, $\Delta 85$, $\Delta 86$) inserts were isolated by PCR using the following 5'

PCT/US05/03656-26052005

primers (ST3 BamH1 Δ 73) TGTATCGGATCCCTGGCCACCAAGTACGCTAACTT (SEQ ID NO:72); (ST3 BamH1 Δ 85)

TGTATCGGATCCTGCAAACCCGGCTACGCTTCAGCCAT (SEQ ID NO:73); and (ST3

PCT/US05/03956-26052005

BamHI Δ 86) TGTATCGGATCCAAACCCGGCTACGCTTCAGCCAT (SEQ ID NO:74) respectively, in pairs with the common 3' primer (ST3-XhoI)GGTCTCCTCGAGTCAGATAACCACTGCTTAA (SEQ ID NO:75). Each PCR product was digested with BamHI and XhoI, subcloned into BamHI-XhoI digested pCWin2-MBP Kanr vector, transformed into TB1 cells, and screened for the correct construct.

[0316] PCR reactions were carried out under the following conditions. One cycle at 95°C for 1 minute. One μ l vent polymerase was added. Ten of the following cycles were performed: 94°C for 1 minute; 65°C for 1 minute; and 72°C for 1 minute. After a final ten minutes at 72°C, the reaction was cooled to 4°C.

[0317] All of the ST3GalIII truncations had activity after refolding. The experiments described below were performed using the MBP Δ 73ST3GalIII truncation.

Expression of MBP-ST3GalIII in *E. coli* TB1 cells

[0318] The pMAL-ST3GalIII plasmid was transformed into chemically competent *E. coli* TB1 cells. Three isolated colonies containing TB1/pMAL-ST3GalIII construct were picked from the LB agar plates. The colonies were grown in five ml of LB media supplemented with 60 μ g/ml carbenicillin at 37°C with shaking until the liquid cultures reached an OD₆₂₀ of 0.7. Two one ml aliquots were withdrawn from each culture and used to inoculate fresh media with or without 500 μ M IPTG (final). The cultures were grown at 37°C for two hours. Bacterial cells were harvested by centrifugation. Total cell lysates were prepared heating the cell pellets in the presence of SDS and DTT. IPTG induced expression of MBP-ST3GalIII. (Data not shown.)

Expression of MBP-ST3GalIII and Purification of the inclusion bodies:

[0319] A one ml aliquot of TB1/pMAL-ST3GalIII overnight culture was inoculated into 0.5 liter of LB media with 50 μ g/ml carbenicillin and grown to an OD₆₂₀ of 0.7. Expression of MBP-ST3GalIII was induced by addition of 0.5 mM IPTG, followed by overnight incubation at room temperature. The next day bacterial cells were harvested by centrifugation. Cell pellets were resuspended in a buffer containing 75 mM TrisHCl, pH 7.4; 100 mM NaCl; and 1 % glycerol. Bacterial cells were lyzed using a French Press. Soluble and insoluble fractions were separated by centrifugation for thirty minutes, 4°C, 10,000 rpm, Sorvall, SS 34 rotor). Soluble and insoluble fractions were separated by centrifugation for thirty minutes at 10,000RPM in a Sorvall, SS 34 rotor at 4°C.

PCT/US75/03855, 26092005

buffer was supplemented with 0.3 mM Lauryl maltoside (LM); 0.1 mM oxidized glutathione (GSSG); 1 mM reduced glutathione (GSH) immediately before the addition of solubilized IB's. Two ml of solubilized IB's were added into 43 ml of refolding buffer in 50 ml sterile culture tube. The tube was placed on a rocker-shaker and gently shaken for 24 hours at 4°C.

- 5 The refolded protein was dialyzed in dialysis tubing (MWCO: 7 kD) against Dialysis Buffer (100 mM Tris HCl, pH 7.5; 100 mM NaCl; and 5 % glycerol) twice (in 10-20 volume excess buffer).

[0330] The large scale dialyzed, refolded MBP-Gal III was analyzed for ST3GalIII activity, and exhibited about 53.6 U/g IB.

10 Example 2: Site Directed Mutagenesis of Human GnTI to Enhance Refolding.

- [0331] A truncated human N-acetylglucosaminyltransferase I (103 amino terminal amino acids deleted) was expressed in *E.coli* as a maltose binding fusion protein (GnTI/MBP). The fusion protein was insoluble and was expressed in inclusion bodies. After solubilization and refolding, the GnTI/MBP fusion protein had low activity. The crystal structure of a truncated form of rabbit GnTI (105 amino terminal amino acids deleted) shows an unpaired cysteine residue (CYS123) near the active site. (See, *e.g.*, Unligil *et al.*, *EMBO J.* 19:5269-5280 (2000)). The corresponding unpaired cysteine in the human GnTI was identified as CYS121 and was replaced with a series of amino acids that are similar in size and chemical characteristics. The amino acids used include serine (Ser), threonine (Thr), alanine (Ala) and aspartic acid (Asp). In addition, a double mutant, ARG120ALA, CYS121HIS, was also made. The mutant GnTI/MBP fusion proteins were expressed in *E. coli*, refolded and assayed for GnTI activity towards glycoproteins.
- 15
- 20

- [0332] Mutagenesis was done using a Quick Change Site-Directed Mutagenesis Kit from Stratagene. Additional restriction sites were introduced with some of the GnT1 mutations.
- 25 For example an *ApaI* site (underlined, GGGCCAC) was introduced into the GnT1 ARG120ALA, CYS121HIS mutant, *i.e.*, CGC CTG → **GCC CAC** (changes in bold). The following mutagenic oligonucleotides were used to make the double mutant: GnT1 R120A, C121H+, 5'CCGCAGCACTGTTCGGG**CCCCAC**CCTGGACAAGCTGCTG 3' (SEQ ID NO:76); and GnT1 R120A, C121H-
- 30 5'CAGCAGCTTGTCCAGGTGGG**CCCCGA**ACAGTGCTGCGG 3' (SEQ ID NO:77) (changes shown in bold). An *AscI* site (underlined, GGCGCGCC) was introduced into the

PCT/US05/03856 26052005

GnT1 CYS121ALA mutant, *i.e.*, CTG → **GCC** (changes in bold). The following mutagenic oligonucleotides were used to make the GnT1 CYS121ALA mutant: GnT1C123A+

PCT/US05/03856 - 26052005

5'AGCACTGTTTCGGCGCGCCCTGGACAAGCTGCTG 3' (SEQ ID NO:78); and
 GnT1C123A-5'CAGCAGCTTGTCCAGGGCGCGCCGAACAGTGCT 3' (SEQ ID
 NO:79).

[0333] The activity of the mutant proteins expressed in *E. coli* was compared to the activity
 of wild type GnT1 expressed in baculovirus. A CYS121SER GNTI mutant was active in a
 TLC based assay. In contrast, a CYS121THR mutant had no detectable activity and a
 CYS121ASP mutant had low activity. A CYS121ALA mutant was very active, and a double
 mutant, ARG120ALA, CYS121HIS, based on the amino acid sequence of the *C. elegans*
 GnT1 protein (Gly14), also exhibited activity, including transfer of GlcNAc to glycoproteins.
 Amino acid and encoding nucleic acid sequences of the GnT1 mutants are provided in
 Figures 7-11.

[0334] A second GnT1 truncation was made and fused to MBP: MBP-GnT1(D35). Figure
 35 provides a schematic of the MBP-GnT1 fusion proteins, and depicts the truncations, e.g.,
 $\Delta 103$ or $\Delta 35$, and the Cys121Ser mutation (top). The bottom of the figure provides the full
 length human GnT1 protein. Mutations of Cys121 were also made in the MBP-GnT1(D35)
 protein.

[0335] Both fusion proteins were expressed in *E. coli* and both had activity for remodeling
 of the RNase B glycoprotein. Figure 36 provides an SDS-PAGE gel showing in the right
 panel the refolded MBP-GnT1 fusion proteins: MBP-GnT1(D35) C121A, MBP-GnT1(D103)
 R120A + C121H, and MBP-GnT1(D103) C121A. The left panel shows the activities for
 remodeling the RNase B glycoprotein of two different batches (A1 and A2) of refolded
 MBP-GnT1(D35) C121A at different time points. The MBP-GnT1 (D103) C121A also
 remodeled the RNase B glycoprotein. Data not shown.

Example 3: MPB fusions to GalT1.

[0336] The following fusions between truncated bovine GalT1 and MBP were constructed:
 MBP-GalT1 (D129) wt, (D70) wt or (D129 C342T). (For the full length bovine sequence,
 see, e.g., D'Agostaro *et al.*, *Eur. J. Biochem.* 183:211-217 (1989) and accession number
 CAA32695.) Each construct had activity after refolding. The amino acid sequence of the
 full length bovine GalT1 protein is provided in Figure 30. The mutants are depicted
 schematically in Figure 31 with a control protein GalT1(40) (S96A+C342T). See, e.g.,
 Ramakrishnan *et al.*, *J. Biol. Chem.* 276:37666-37671 (2001).

[0337] MBP-GalT1 (D70) was expressed in *E. coli* strain JM109. After overnight induction with IPTG, inclusion bodies were isolated from the insoluble pellet after cells were

Example 5: Refolding eukaryotic GalNAcT2.

[0365] A truncated human GalNAcT2 enzyme was expressed in *E. coli* and used to determine optimal conditions for solubilization and refolding using the methods described above. The full length human GalNAcT2 nucleic acid and amino acid sequences are provided in Figures 13A and B. The sequences of the mutant protein, GalNAcT2(D51), are shown in Figures 14A and B. The mutant was expressed in *E. coli* as an MBP fusion protein, MBP-GalNAcT2(D51). Other GalNAcT2 mutants were made, expressed in *E. coli* and were able to be refolded: MBP-GalNAcT2(D40), MBP-GalNAcT2(D73), and MBP-GalNAcT2(D94). Data not shown. Details of the construction of the additional deletion mutants is found in USSN 60/576,530, filed June 3, 2004 and USSN 60/598,584, August 3, 2004, both of which are herein incorporated by reference for all purposes.

[0366] Cultures of bacteria expressing MBP-GalNAcT2(D51) were grown and harvested as described above. Inclusion bodies were purified from bacteria as described above. Solubilization of the inclusion bodies was performed at pH 6.5 or at pH 8.0. After solubilization, MBP-GalNAcT2(D51) protein was refolded at either pH 6.5 or pH 8.0 using buffers A and B, *i.e.*, **Buffer A**: 55 mM MES pH 6.5, 550 mM Arginine, 0.055 % PEG3350, 264 mM NaCl, 11 mM KCl, supplemented with 1 mM GSH, 0.1 mM GSSG; and **Buffer B**: 55 mM TrisHCl pH 8, 550 mM Arginine, 0.055 % PEG3350, 264 mM NaCl, 11 mM KCl, supplemented with 1 mM GSH, 0.1 mM GSSG. After refolding, MBP-GalNAcT2(D51) protein was dialyzed and then concentrated. Figure 15 provides a demonstration of the protein concentration of refolded MBP-GalNAcT2(D51) after solubilization at pH 6.5 or pH 8.0 and refolding at pH 6.5 or pH 8.0.

[0367] A radiolabeled [³H]-UDP-GalNAc assay was performed to determine the activity of the *E. coli*-expressed refolded MBP-GalNAcT2(D51) by monitoring the addition of radiolabeled GalNAc to a peptide acceptor. The acceptor was a MuC-2 – like peptide having the sequence MVTPTPTPTC (SEQ ID NO:80). The peptide was dissolved in 1M Tris-HCl pH=8.0. See, *e.g.*, USSN 60/576,530 filed June 3, 2004; and US provisional patent application Attorney Docket Number 040853-01-5149-P1, filed August 3, 2004; both of which are herein incorporated by reference for all purposes. Figure 16 provides a demonstration of the enzymatic activity of refolded MBP-GalNAcT2(D51) after solubilization at pH 6.5 or pH 8.0 and refolding at pH 6.5 or pH 8.0. Figure 17 provides a demonstration of the specific activity of refolded MBP-GalNAcT2(D51) after solubilization

PCT/US05/03856, 26052015

at pH 6.5 or pH 8.0 and refolding at pH 6.5 or pH 8.0. The highest activity levels were observed with MBP-GalNAcT2(D51) that